BioDelivery Sciences

BioDelivery Sciences is a pharmaceutical company that focuses on pain management and addiction medicine. They are utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here is how BioDelivery Sciences International (BDSI) and Vertex Pharmaceuticals (VRTX) have performed compared to their sector so far this year.

Has BioDelivery Sciences International (BDSI) Outpaced Other Medical Stocks This Year?

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

BioDelivery Sciences International (BDSI) Just Flashed Golden Cross Signal: Do You Buy?

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults

BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine

NEW ORLEANS, Feb. 16, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

BIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioDelivery Sciences International, Inc. - BDSI

Wilmington, Delaware--(Newsfile Corp. - February 15, 2022) - Rigrodsky Law, P.A. is investigating BioDelivery Sciences International, Inc. ("BioDelivery") (NASDAQ: BDSI) regarding possible breaches of fiduciary duties and other violations of law related to BioDelivery's agreement to be acquired by Collegium Pharmaceutical, Inc. Under the terms of the agreement, BioDelivery's shareholders will receive $5.60 in cash for each share of BioDelivery common stock they own.To learn more about this investigation and your rights, visit:...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioDelivery Sciences International, Inc. Buyout

Collegium Pharmaceutical

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioDelivery Sciences International, Inc. ("BioDelivery" or the "Company") (NASDAQ: BDSI), in connection with the proposed acquisition of the Company by Collegium Pharmaceutical, Inc. ("Collegium") (NASDAQ: COLL) via a tender offer.  Under the terms of the acquisition agreement, the Company's shareholders will receive $5.60 in cash for each share of BioDelivery common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioDelivery Sciences International, Inc.

Collegium (COLL) is set to acquire BioDelivery (BDSI) for approximately $604 million in cash. The transaction is likely to be completed by the end of first-quarter 2022.

BioDelivery (BDSI) Stock Surges on Buyout Offer From Collegium

Today, a big takeover announcement has sent shares of BioDelivery and BDSI stock soaring more than 50% on investor enthusiasm for this deal. The post BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing Today appeared first on InvestorPlace.

BDSI Stock Alert: The Deal Sending Little-Known BioDelivery Skyrocketing Today

Cornerstone Building Brands Inc

Markets opened lower on Monday morning, but nothing held these two companies back.

Merger Mania Is Sending These 2 Little-Known Stocks Soaring

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Collegium Pharmaceutical, Inc. for $5.60 per share is fair to BioDelivery shareholders. Halper Sadeh encourages BioDelivery shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigat

BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to Shareholders

CURO Group Hlds

Hooker Furniture

When seeking value opportunities, investors could be interested in the following stocks, since their prices are trading at a discount to the intrinsic value calculated by GuruFocus' earnings-based discounted cash flow (DCF) calculator.

3 Potential Value Opportunities to Consider

MILWAUKEE, Feb. 14, 2022 /PRNewswire/ -- Ademi LLP is investigating BioDelivery Sciences (NASDAQ: BDSI) for possible breaches of fiduciary duty and other violations of law in its transaction with Collegium.  Click here to learn how to join the action: https://www.ademilaw.com/case/biodelivery-sciences-international-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether BioDelivery Sciences International, Inc. has obtained a Fair Price in its transaction with Collegium.

Kaival Brands Innovations Group

Motus GI Hlds

Check these penny stocks out for your watchlist today The post Trading Penny Stocks? Top Stock Market News for February 14th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for February 14th, 2022

Collegium Pharmaceutical Inc (NASDAQ: COLL) will acquire BioDelivery Sciences International Inc (NASDAQ: BDSI) at $5.60 per share in an all-cash transaction, corresponding to an equity value of approximately $604 million. The consideration represents a 54% premium to BDSI common stock's closing price of $3.64 on February 11 and a premium of 65% over the 30 trading days volume-weighted average price of $3.40.

Collegium Pharma Broadens Its Pain Portfolio With $600M BioDelivery Sciences Deal

Shares of BioDelivery Sciences International Inc. BDSI, -1.62% blasted 51.7% higher to pace all premarket gainers Monday, after the specialty pharmaceutical company with a portfolio of pain and neurology products agreed to be acquired by Collegium Pharmaceutical Inc. COLL, -0.23% in a deal valued at about $604 million. Collegium's stock was still inactive ahead of the open.

BioDelivery's stock rockets toward a 2-year high after buyout deal with Collegium at a 54% premium

Transaction is valued at $5.60 per share representing a total equity value of $604 million

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

BioDelivery (BDSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for BioDelivery (BDSI)

Let's see if BioDelivery (BDSI) stock is a good choice for value-oriented investors right now from multiple angles.

Should Value Investors Pick BioDelivery (BDSI) Stock Now?

Shares of the small pharmaceutical company, which focuses on pain management, have been rising since it released updated guidance late last week.

Why Shares of BioDelivery Sciences International Jumped 12.2% on Monday

Alto Ingredients

Hall of Fame Resort & Entertainment

Here are three penny stocks to watch with the stock market down today The post Best Penny Stocks to Buy During The Down Market? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy During The Down Market? 3 to Watch

Bon Natural Life Ltd

Vivos Therapeutics

Here are three penny stocks you should add to your watchlist The post These 3 Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These 3 Penny Stocks Exploded Today, Here's Why

BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.

BioDelivery (BDSI) Stock Up on Raised Guidance for 2021

The stock price of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) increased by 26.92% today. This is why it happened.

BioDelivery Sciences Stock (BDSI): Why The Price Surged Today

The biotech company received a favorable court ruling regarding its lead therapy.

News for BioDelivery Sciences Stock (BDSI)